Nytt läkemedel mot Crohns sjukdom

Zealand Pharma tar en ny behandling till klinisk prövning

Helge Sander: "Fler kvinnor behövs"

- Det är något fel när det ena könet i stort sett väljer bort en karriär som forskare, säger Danmarks forskningsminister. Idag håller han rundabordssamtal för att diskutera varför kvinnliga forskare missgynnas. Han välkomnar alla lösningar, utom en.

Ny skola for global hälsa

Sjukdom och hälsa i utvecklingsländer blir ett nytt insatsområde för Köpenhamns universitet. Idag invigs ett nytt centrum som bland annat ska arbeta med malaria och hiv.

Success fee to Bioinvent and partner

The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.

New CEO to Promedvi

Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.

New member to Active board

The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.

EUR 2 million for peanut allergies

ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.

Medtech companies find new beam technique

The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.

Eli Lilly writes biotech fine history

The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.

Abbott expands by acquisition

An acquisition gives Abbott a leadership position in another large and growing medical device segment.

View pathology images in your iPhone

The Institute for Medical Informatics in Oslo announces a brand new iPhone application for virtual microscopy.

Vitrolife wants to acquire Medicult

The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.

Norwegian cancer therapy leaves phase II

New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.

Bio-Linux goes global

Recently the NEBC Bio-Linux Version 5.0 was released, a one-stop shop for bioinformatics tools in a Linux context.

Medtech giant separates

Due to the global economic situation, the medtech companies Q-Med and the Palomar Medical Technologies has terminated its international agreement.

Swedish cancer therapy granted

Pledpharma, Linköping University and Ryhov County Hospital receive a research grant from the Research Council FORSS to conduct clinical studies in cancer patients.

Glucose facilitates the use of indigo

The Finnish researcher Anne Vuorema oat the MTT Agrifood Research Finland proves in her new doctoral dissertation that glucose can serve as a reducing agent of indigo.

New influenza vaccine to EU

The Astrazeneca subsidary Medimmune submits marketing authorisationapplication in EU for an new intranasal vaccine against influenza.

Pfizer buys Swiss vaccines

Pfizer executes commercial license agreements for novel human vaccines based on the Swiss company Cytos Biotechnology's Immunodrug technology.

Academy for a new turn at work

Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.

Sales Representative, Applied Biosystems

Bring talent to those in need

Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.

Ambassador program makes MVA big in Japan

The first ambassadors of the Medicon Valley Ambassador Programme have only worked in each other's countries for six months. But they have already made a significant difference for their sister clusters.